Novo Nordisk (NOVOB DC) Q1 (DKK): Sales 65.35bln (exp. 63.2bln), Wegovy sales 9.38bln (exp. 10.55bln), Net 25.4bln (exp. 23.4bln), EBIT 31.85bln (exp. 29.04bln), EPS 5.68 (exp. 5.23), Gross margin 84.8% (exp. 84.7%)
- Diabetes/Obesity Care sales 61bln, +27%; mainly driven by GLP-1 diabetes sales growth of 32% at CER & Obesity care to 11bln, +42% at CER.
- Number of patients starting on Wegovy in the US has quadrupled Y/Y.
- US demand for Wegovy still exceeds supply.
Q1 Sales Breakdown
- Total GLP-1 34.98bln (exp. 34.78bln, prev. 26.7bln)
- Injectable GLP-1 29.9bln (prev. 22.45bln)
- Ozempic 27.8bln (prev. 19.6bln)
- Victoza 2.16bln (prev. 2.8bln)
- Rybelsus 5bln (preb. 4.35bln)
- Wegovy 9.37bln (prev. 4.5bln)
- Saxenda 1.65bln (prev. 3.27bln)
FY Guidance
- Sales +19 to +27% (exp. +25.9%) at CER
- Operating Profit +22% to +30% at CER.
via Novo Nordisk
Analysis details (06:32)
- Largest component in the Stoxx 600 with a 3.5% weighting.
- Earnings call is scheduled for 12:00BST.
02 May 2024 - 06:31- Important- Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts